AU2007321111A1 - Colonic delivery using Zn/pectin beads with a Eudragit coating. - Google Patents

Colonic delivery using Zn/pectin beads with a Eudragit coating. Download PDF

Info

Publication number
AU2007321111A1
AU2007321111A1 AU2007321111A AU2007321111A AU2007321111A1 AU 2007321111 A1 AU2007321111 A1 AU 2007321111A1 AU 2007321111 A AU2007321111 A AU 2007321111A AU 2007321111 A AU2007321111 A AU 2007321111A AU 2007321111 A1 AU2007321111 A1 AU 2007321111A1
Authority
AU
Australia
Prior art keywords
human
drug delivery
delivery system
agent
eudragit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007321111A
Other languages
English (en)
Inventor
Antoine Andremont
Helene-Celine Huguet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Da Volterra SAS
Original Assignee
Da Volterra SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Da Volterra SAS filed Critical Da Volterra SAS
Publication of AU2007321111A1 publication Critical patent/AU2007321111A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2007321111A 2006-11-17 2007-11-16 Colonic delivery using Zn/pectin beads with a Eudragit coating. Abandoned AU2007321111A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85959906P 2006-11-17 2006-11-17
US85960006P 2006-11-17 2006-11-17
US60/859,600 2006-11-17
US60/859,599 2006-11-17
PCT/EP2007/062475 WO2008059062A1 (en) 2006-11-17 2007-11-16 Colonic delivery using zn/pectin beads with a eudragit coating.

Publications (1)

Publication Number Publication Date
AU2007321111A1 true AU2007321111A1 (en) 2008-05-22

Family

ID=39181811

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007321111A Abandoned AU2007321111A1 (en) 2006-11-17 2007-11-16 Colonic delivery using Zn/pectin beads with a Eudragit coating.

Country Status (7)

Country Link
EP (1) EP2081557A1 (ja)
JP (1) JP2010510196A (ja)
CN (1) CN101795675A (ja)
AU (1) AU2007321111A1 (ja)
BR (1) BRPI0719319A2 (ja)
CA (1) CA2678131A1 (ja)
WO (1) WO2008059062A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009040030A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2009033707A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20100184680A1 (en) * 2007-09-11 2010-07-22 Dorian Bevec Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
PT2538930T (pt) 2010-02-23 2016-08-05 Da Volterra Formulações para administração oral de adsorventes no intestino
BR112012024877A2 (pt) * 2010-04-08 2016-06-14 Merz Pharma Gmbh & Co Kgaa preenchedor, processo para o preparo de um preenchedor e dispositivo de injeção
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
US9907755B2 (en) * 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
JP6522584B2 (ja) * 2013-04-26 2019-05-29 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ 腎不全を処置するための組成物及び方法
US20160279187A1 (en) * 2013-10-31 2016-09-29 University Of Hawaii Calpain inhibitors for ibd and colorectal cancer treatment
HUE047062T2 (hu) 2013-12-18 2020-04-28 The George Washington Univ A Congressionally Chartered Not For Profit Corporation Angiotenzin II alacsony vérnyomás kombinációs kezelésére
EP3083031B1 (en) 2013-12-20 2019-10-16 Fresenius Kabi Deutschland GmbH Microcapsules with polymeric coating comprising a lipid and an active agent
CN107072950B (zh) * 2014-09-11 2020-11-03 嘉利达股份有限公司 明胶/果胶粒子
US20160158174A1 (en) * 2014-12-09 2016-06-09 Intercontinental Great Brands Llc Enteric-Coated Functional Food Ingredients And Methods For Making The Enteric-Coated Functional Food Ingredients
AU2017205168A1 (en) 2016-01-07 2018-08-16 La Jolla Pharma, Llc Methods for administering angiotensin II
WO2018005606A1 (en) * 2016-06-28 2018-01-04 Synthetic Biologics, Inc. Microbiome protection from oral antibiotics
US11771656B2 (en) * 2016-11-17 2023-10-03 Shanghai Jiaotong University School Of Medicine Oral colon-targeted delivery system and preparation method and application thereof
DE102017000896A1 (de) * 2017-02-01 2018-08-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Selektives Freisetzungssystem für Tumortherapeutika und Tumordiagnostika sowie Biosensor für Tumorgewebe
WO2018191678A1 (en) 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
RU2375047C2 (ru) * 2004-03-26 2009-12-10 Лек Фармасьютиклз Д.Д. Фармацевтическая лекарственная форма, устойчивая к действию желудочного сока, включающая n-(2-(2-фталимидоэтокси)ацетил)-l-аланил-d-глутаминовую кислоту (lk 423)
DK1883396T3 (da) * 2005-05-18 2013-10-07 Centre Nat Rech Scient Afgivelse af adsorptionsmidler til tyktarmen

Also Published As

Publication number Publication date
JP2010510196A (ja) 2010-04-02
CA2678131A1 (en) 2008-05-22
CN101795675A (zh) 2010-08-04
EP2081557A1 (en) 2009-07-29
BRPI0719319A2 (pt) 2014-02-04
WO2008059062A1 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
AU2007321111A1 (en) Colonic delivery using Zn/pectin beads with a Eudragit coating.
US20080124279A1 (en) Colonic delivery using Zn/pectin beads with a Eudragit coating
US20080317666A1 (en) Colonic Delivery of Active Agents
KR101080577B1 (ko) 활성성분의 결장 표적화 전달을 위한 제제
US8303989B2 (en) Compositions and methods for increasing the oral absorption of antimicrobials
CA2413251C (en) Compositions and methods to improve the oral absorption of antimicrobial agents
KR20190127984A (ko) 지연 방출형 약물 제형
Prasanth et al. Colon specific drug delivery systems: a review on various pharmaceutical approaches
RU2282462C2 (ru) Композиции и способы улучшения перорального всасывания противомикробных средств
JP2013525351A (ja) ナノ粒子の医薬組成物
US20220241383A1 (en) Alkaline phosphatase agents for treatment of neurodevelopmental disorders
US8273376B2 (en) Colonic delivery of metallo-dependent enzymes
US20220202721A1 (en) Articles and methods for administration of therapeutic agents
Iswandana et al. Delivery of Potential Drugs to The Colon: Challenges and Strategies.
Patel et al. Colon targeted drug delivery: Approaches and newer technology

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted